Company / Working Capital
Edwards Lifesciences Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$4.9B
FY2025
5-year range
$2.1B / $4.9B
FY2021-FY2025
Trend
+3.0%
vs FY2024
Sector context
#10 of 160
Health Care
What the data says
Among 160 Health Care companies, Edwards Lifesciences is in the top 6% for working capital. Working Capital has increased for 3 consecutive years, from $2.1B in FY2022 to $4.9B in FY2025.
Based on SEC 10-K filings.
$4.9B in FY2025 with a 5-year CAGR of +17.5%. Top quartile in the Health Care sector.
Improved from $2.8B to $4.9B over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +33.4%
- 5-Year CAGR
- +17.5%
- 10-Year CAGR
- -
Sector benchmark
Top 6% in Health CareTop 6% of 160This company $4.9B Sector average $757.1M
▼
+550.6% above sector average
Key checks
Key Insights
- Edwards Lifesciences's working capital has grown for 3 consecutive years.
- 5-year CAGR of +17.5%, indicating consistent growth.
- In FY2025, working capital increased 3.0% year-over-year.
- Ranks #10 out of 160 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.16 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.9B | +3.0% |
| FY2024 | $4.8B | +68.3% |
| FY2023 | $2.8B | +37.0% |
| FY2022 | $2.1B | -3.5% |
| FY2021 | $2.1B | -2.2% |
| FY2020 | $2.2B | +5.5% |
| FY2019 | $2.1B | +47.6% |
| FY2018 | $1.4B | +24.9% |
| FY2017 | $1.1B | -33.9% |
| FY2016 | $1.7B | +8.6% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026